MUSC Spin-Off Company to Test Regenerative Wound H...(surprised by the feedback from the inves...)

Recently, FSR was chosen as one of four finalists among 40 companies that competed for the chance to present their work to the investment community across the Southeast during the Southeast Biotechnology Forum (SEBIO).

"SEBIO is the premier venue in the Southeast for young life sciences companies to test their marketability, and as such, we are privileged to have been selected as a finalist," said FSR CEO Spencer Robert. "We went through multiple review processes, each conducted by a mixture of successful entrepreneurs, venture capitalists and other industry experts. The publicity and interest we received from the event was invaluable. Our secret is definitely out."

Additionally, FSR is collaborating with MUSC on a National Institutes of Health-National Institute of Diabetic Digestive Kidney Diseases grant to study the peptide in treating diabetic wounds. The two entities are also working together on examining the peptide's efficacy in treating spinal cord injuries. This work is in the preliminary stages and has not yet progressed to clinical trials. The Office of Naval Research has also expressed interest in FSR's technology, which may be used to develop projects that will look at how the peptides could be used to treat injured soldiers on the battlefield.

How it works: The skin's wound repair process is initiated immediately after injury and involves inflammation, proliferation, scar production, and tissue remodeling. One of the common complications in wound healing is excessive scarring. Gourdie and Ghatnekar developed the bioengineered peptide based on a naturally occurring protein in the body that helps regulate communication between cells. This peptide accelerated wound healing and tissue regeneration with significantly reduced scarring in laboratory animal tests, and leads researchers to believe that it will promote faster healing, reduced scar
'/>"/>